Thank you, Mr. Chair.
Thank you to our witnesses for appearing before us this evening. My question is for Dr. Lyon.
My understanding is that you also do research internationally. From your research on how assisted dying has developed across different countries, could you walk us through a specific example where eligibility expanded over time? What drove that change in practice?